Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian CancerJurriaan Brouwer‐Visser(Montefiore Medical Center), Gloria S. Huang(Regeneron (United States))PLoS ONEJune 16, 201410.1371/journal.pone.0100165Cited by 39SaveCiteExport RISWatch citationsRelated PapersOdronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study|Blood|2024|28Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study|Blood|2023|8Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study|Blood|2024|2